vs
Fortive（FTV）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Fortive的季度营收约是Royalty Pharma plc的1.7倍（$1.1B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 12.8%，领先21.7%），Fortive同比增速更快（7.7% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -17.0%）
Fortive是总部位于美国华盛顿州埃弗里特的工业科技集团，专注于提供互联工作流解决方案所需的核心技术，研发、生产及销售专业工程类产品、软件与服务，旗下业务分为智能运营解决方案、精密技术、先进医疗解决方案三大战略板块。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FTV vs RPRX — 直观对比
营收规模更大
FTV
是对方的1.7倍
$622.0M
营收增速更快
FTV
高出2.9%
4.8%
净利率更高
RPRX
高出21.7%
12.8%
两年增速更快
RPRX
近两年复合增速
-17.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $622.0M |
| 净利润 | $136.4M | $214.2M |
| 毛利率 | 63.2% | — |
| 营业利润率 | 17.9% | 62.4% |
| 净利率 | 12.8% | 34.4% |
| 营收同比 | 7.7% | 4.8% |
| 净利润同比 | 21.1% | 2.9% |
| 每股收益（稀释后） | $0.44 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTVRPRX
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $622.0M | ||
| Q3 25 | $1.0B | $609.3M | ||
| Q2 25 | $1.5B | $578.7M | ||
| Q1 25 | $1.5B | $568.2M | ||
| Q4 24 | $1.6B | $593.6M | ||
| Q3 24 | $1.5B | $564.7M | ||
| Q2 24 | $1.6B | $537.3M |
净利润FTVRPRX
| Q1 26 | $136.4M | — | ||
| Q4 25 | $185.7M | $214.2M | ||
| Q3 25 | $55.0M | $288.2M | ||
| Q2 25 | $166.6M | $30.2M | ||
| Q1 25 | $171.9M | $238.3M | ||
| Q4 24 | $208.8M | $208.2M | ||
| Q3 24 | $221.6M | $544.0M | ||
| Q2 24 | $195.1M | $102.0M |
毛利率FTVRPRX
| Q1 26 | 63.2% | — | ||
| Q4 25 | 63.2% | — | ||
| Q3 25 | 63.2% | — | ||
| Q2 25 | 59.0% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 60.0% | — | ||
| Q2 24 | 59.8% | — |
营业利润率FTVRPRX
| Q1 26 | 17.9% | — | ||
| Q4 25 | 20.1% | 62.4% | ||
| Q3 25 | 15.5% | 70.1% | ||
| Q2 25 | 14.6% | 36.3% | ||
| Q1 25 | 15.8% | 94.0% | ||
| Q4 24 | 19.0% | 60.9% | ||
| Q3 24 | 19.3% | — | ||
| Q2 24 | 19.4% | 50.2% |
净利率FTVRPRX
| Q1 26 | 12.8% | — | ||
| Q4 25 | 16.5% | 34.4% | ||
| Q3 25 | 5.4% | 47.3% | ||
| Q2 25 | 11.0% | 5.2% | ||
| Q1 25 | 11.7% | 41.9% | ||
| Q4 24 | 12.9% | 35.1% | ||
| Q3 24 | 14.4% | 96.3% | ||
| Q2 24 | 12.6% | 19.0% |
每股收益（稀释后）FTVRPRX
| Q1 26 | $0.44 | — | ||
| Q4 25 | $0.60 | $0.49 | ||
| Q3 25 | $0.16 | $0.67 | ||
| Q2 25 | $0.49 | $0.07 | ||
| Q1 25 | $0.50 | $0.55 | ||
| Q4 24 | $0.60 | $0.46 | ||
| Q3 24 | $0.63 | $1.21 | ||
| Q2 24 | $0.55 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $356.1M | $618.7M |
| 总债务越低越好 | $3.5B | $9.0B |
| 股东权益账面价值 | $6.1B | $9.7B |
| 总资产 | $11.6B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.57× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FTVRPRX
| Q1 26 | $356.1M | — | ||
| Q4 25 | $375.5M | $618.7M | ||
| Q3 25 | $430.8M | $938.9M | ||
| Q2 25 | $1.8B | $631.9M | ||
| Q1 25 | $892.1M | $1.1B | ||
| Q4 24 | $813.3M | $929.0M | ||
| Q3 24 | $811.3M | $950.1M | ||
| Q2 24 | $644.1M | $1.8B |
总债务FTVRPRX
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.2B | $9.0B | ||
| Q3 25 | $3.3B | $8.9B | ||
| Q2 25 | $4.8B | $8.0B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $3.7B | $7.6B | ||
| Q3 24 | $3.9B | $7.6B | ||
| Q2 24 | $3.8B | $7.6B |
股东权益FTVRPRX
| Q1 26 | $6.1B | — | ||
| Q4 25 | $6.5B | $9.7B | ||
| Q3 25 | $6.5B | $9.6B | ||
| Q2 25 | $10.4B | $9.5B | ||
| Q1 25 | $10.2B | $9.8B | ||
| Q4 24 | $10.2B | $10.3B | ||
| Q3 24 | $10.6B | $10.3B | ||
| Q2 24 | $10.5B | $9.8B |
总资产FTVRPRX
| Q1 26 | $11.6B | — | ||
| Q4 25 | $11.7B | $19.6B | ||
| Q3 25 | $11.9B | $19.3B | ||
| Q2 25 | $18.2B | $18.3B | ||
| Q1 25 | $17.1B | $17.6B | ||
| Q4 24 | $17.0B | $18.2B | ||
| Q3 24 | $17.5B | $18.0B | ||
| Q2 24 | $17.3B | $17.7B |
负债/权益比FTVRPRX
| Q1 26 | 0.57× | — | ||
| Q4 25 | 0.50× | 0.92× | ||
| Q3 25 | 0.51× | 0.93× | ||
| Q2 25 | 0.46× | 0.84× | ||
| Q1 25 | 0.38× | 0.78× | ||
| Q4 24 | 0.36× | 0.74× | ||
| Q3 24 | 0.37× | 0.74× | ||
| Q2 24 | 0.36× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $234.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $193.8M | — |
| 自由现金流率自由现金流/营收 | 18.1% | — |
| 资本支出强度资本支出/营收 | 2.5% | — |
| 现金转化率经营现金流/净利润 | 1.72× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $935.2M | — |
8季度趋势，按日历期对齐
经营现金流FTVRPRX
| Q1 26 | $234.8M | — | ||
| Q4 25 | $1.1B | $827.1M | ||
| Q3 25 | $164.4M | $702.6M | ||
| Q2 25 | $311.2M | $364.0M | ||
| Q1 25 | $241.7M | $596.1M | ||
| Q4 24 | $502.2M | $742.5M | ||
| Q3 24 | $459.0M | $703.6M | ||
| Q2 24 | $308.9M | $658.2M |
自由现金流FTVRPRX
| Q1 26 | $193.8M | — | ||
| Q4 25 | $313.8M | — | ||
| Q3 25 | $153.1M | — | ||
| Q2 25 | $274.5M | — | ||
| Q1 25 | $215.0M | — | ||
| Q4 24 | $465.2M | — | ||
| Q3 24 | $431.2M | — | ||
| Q2 24 | $279.7M | — |
自由现金流率FTVRPRX
| Q1 26 | 18.1% | — | ||
| Q4 25 | 28.0% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 14.6% | — | ||
| Q4 24 | 28.7% | — | ||
| Q3 24 | 28.1% | — | ||
| Q2 24 | 18.0% | — |
资本支出强度FTVRPRX
| Q1 26 | 2.5% | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 1.9% | — |
现金转化率FTVRPRX
| Q1 26 | 1.72× | — | ||
| Q4 25 | 5.83× | 3.86× | ||
| Q3 25 | 2.99× | 2.44× | ||
| Q2 25 | 1.87× | 12.06× | ||
| Q1 25 | 1.41× | 2.50× | ||
| Q4 24 | 2.41× | 3.57× | ||
| Q3 24 | 2.07× | 1.29× | ||
| Q2 24 | 1.58× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTV
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
